13% (1354/10336) of patients harbored PIK3CA mutations in MSK-IMPACT Clinical Sequencing Cohort, while 11% (1143/10194) of patients harbored PIK3CA mutations in China Pan-cancer Cohort (OrigiMed2020) (20, 22). This evidence concerns the gene PIK3CA and cancer.